Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NETWORK 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 4Genitourinary 3Plasma cell 1Head & Neck 1

Conditions

Prostatic Neoplasms 3

Interventions

Magnetic Resonance Spectroscopy 106Specimen Handling 87pembrolizumab 81enzalutamide 64Nivolumab 62Gemcitabine 59Docetaxel 51Abiraterone Acetate 44apalutamide 43Radiosurgery 43Androgen Antagonists 43Prednisone 42darolutamide 40Cisplatin 38Biopsy 36Radiotherapy 34cabozantinib 32Carboplatin 30abiraterone 29Pluvicto 29Ipilimumab 29durvalumab 25Leuprolide 24enfortumab vedotin 23X-Rays 23Radiation 23olaparib 20atezolizumab 20Standard of Care 20avelumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
fluciclovine F-18 × Genitourinary × 90 days × Clear all
NCT07569926 2026-06-02

Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

Blue Earth Diagnostics

Phase 4 Not yet recruiting
142 enrolled
Genitourinary

Prostatic Neoplasms

NCT04423211 2026-05-15

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Eastern Cooperative Oncology Group

Phase 3 Recruiting
804 enrolled
Genitourinary

Prostatic Neoplasms

NCT05053152 2026-05-04

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

NRG Oncology

Phase 2 Active not recruiting
194 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡